Capricor Therapeutics

Capricor Therapeutics is an American clinical stage biotechnology company. The company focuses on the development and commercialization of biological therapies for the treatment of duchenne muscular dystrophy (DMD) and other rare disorders. Capricor Therapeutics serves healthcare sector in the United States and Canada.
Capricor Therapeutics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Capricor Therapeutics balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Capricor Therapeutics cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Capricor Therapeutics multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Capricor Therapeutics profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Capricor Therapeutics assets
Capricor Therapeutics cash flows

Capricor Therapeutics dividend policy

The company doesn't provide dividend.

Capricor Therapeutics shares

TickerNameTypeNominal valueISINPrice
CAPR:USCapricor TherapeuticsCommon share-US14070B3096$5.01
Capricor Therapeutics news
11.05.2022
Capricor Therapeutics reported a GAAP loss of $7.818 million for the 3 months of 2022, up 51.7% from $5.152 million in the prior year. The company did not generate revenue. A year earlier the figure was $40,816 thousand.
11.03.2022
Capricor Therapeutics' GAAP loss for 2021 was $20.023 million, up 46.6% from $13.657 million the previous year. Revenue was down 21.1% to $244,898,000 from $310,25,000 a year earlier.
10.11.2021
Capricor Therapeutics' GAAP loss for 9M 2021 was $13.832 million, up 45.9% from $9.479 million in the prior year. Revenue decreased 3% to $244,898,000 from $252,42,000 a year earlier.
13.08.2021
Capricor Therapeutics' GAAP loss for 6M 2021 was $9.9 million, up 77.8% from $5.569 million in the prior year. Revenue increased 4% to $244,898,000 from $235,557,000 a year earlier.
General information
Company nameCapricor Therapeutics
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address8840 WILSHIRE BLVD 2ND FLOOR BEVERLY HILLS CA 90211 (310) 358-3200
Mailing address8840 WILSHIRE BLVD 2ND FLOOR BEVERLY HILLS CA 90211
Websitecapricor.com
Information disclosurewww.sec.gov